Please wait while the formulary information is being retrieved.
Drug overview for QULIPTA (atogepant):
Generic name: atogepant (a-TOE-je-pant)
Drug class: Migraine Prevention Medications
Therapeutic class: Central Nervous System Agents
Atogepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is an antimigraine agent.
No enhanced Uses information available for this drug.
Generic name: atogepant (a-TOE-je-pant)
Drug class: Migraine Prevention Medications
Therapeutic class: Central Nervous System Agents
Atogepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is an antimigraine agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
QULIPTA 60 MG TABLET
QULIPTA 30 MG TABLET
The following indications for QULIPTA (atogepant) have been approved by the FDA:
Indications:
Migraine prevention
Professional Synonyms:
Migraine prophylaxis
Indications:
Migraine prevention
Professional Synonyms:
Migraine prophylaxis
The following dosing information is available for QULIPTA (atogepant):
Dosage adjustment of atogepant is necessary if the drug is used concomitantly with a strong cytochrome P-450 (CYP) 3A4 inhibitor, a CYP3A4 inducer (strong, moderate, or weak), or an organic anion transport protein (OATP) inhibitor.
If concomitant use with a strong CYP3A4 inhibitor (e.g., itraconazole) is necessary, the manufacturer recommends an atogepant dosage of 10 mg once daily.
If concomitant use with a CYP3A4 inducer (e.g., rifampin, ) is necessary, the manufacturer recommends an atogepant dosage of 30 or 60 mg once daily.
If concomitant use with an OATP inhibitor is necessary, the manufacturer recommends an atogepant dosage of 10 or 30 mg once daily.
Avoidance of use or dosage modification of atogepant is necessary if the drug is used concomitantly with a strong CYP3A4 inhibitor, a CYP3A4 inducer (strong, moderate, or weak), or an organic anion transport protein (OATP) inhibitor.
Avoid concomitant use with a strong CYP3A4 inhibitor (e.g., itraconazole).
Avoid concomitant use with a CYP3A4 inducer (e.g., rifampin).
If concomitant use with an OATP inhibitor is necessary, the manufacturer recommends an atogepant dosage of 30 mg once daily.
If concomitant use with a strong CYP3A4 inhibitor (e.g., itraconazole) is necessary, the manufacturer recommends an atogepant dosage of 10 mg once daily.
If concomitant use with a CYP3A4 inducer (e.g., rifampin, ) is necessary, the manufacturer recommends an atogepant dosage of 30 or 60 mg once daily.
If concomitant use with an OATP inhibitor is necessary, the manufacturer recommends an atogepant dosage of 10 or 30 mg once daily.
Avoidance of use or dosage modification of atogepant is necessary if the drug is used concomitantly with a strong CYP3A4 inhibitor, a CYP3A4 inducer (strong, moderate, or weak), or an organic anion transport protein (OATP) inhibitor.
Avoid concomitant use with a strong CYP3A4 inhibitor (e.g., itraconazole).
Avoid concomitant use with a CYP3A4 inducer (e.g., rifampin).
If concomitant use with an OATP inhibitor is necessary, the manufacturer recommends an atogepant dosage of 30 mg once daily.
Atogepant tablets are administered orally without regard to food. Store atogepant tablets at 20-25degreesC (excursions permitted between 15-30degreesC).
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| QULIPTA 60 MG TABLET | Maintenance | Adults take 1 tablet (60 mg) by oral route once daily |
| QULIPTA 10 MG TABLET | Maintenance | Adults take 1 tablet (10 mg) by oral route once daily |
| QULIPTA 30 MG TABLET | Maintenance | Adults take 1 tablet (30 mg) by oral route once daily |
No generic dosing information available.
The following drug interaction information is available for QULIPTA (atogepant):
There are 0 contraindications.
There are 3 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Atogepant/Strong CYP3A4 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Agents that inhibit the CYP3A4 isoenzyme may inhibit the metabolism of atogepant.(1) CLINICAL EFFECTS: Concurrent use of strong CYP3A4 inhibitors may increase levels of and effects from atogepant, including nausea, constipation, and fatigue.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of atogepant recommends that patients on concomitant strong CYP3A4 inhibitors receive atogepant 10 mg once daily for prevention of episodic migraines and avoid use of atogepant for prevention of chronic migraines.(1) DISCUSSION: In a study of healthy subjects, itraconazole, a strong CYP3A4 inhibitor, increased the atogepant area-under-curve (AUC) by 5.5-fold and maximum concentration (Cmax) by 2.15-fold.(1) Strong inhibitors of CYP3A4 include: adagrasib, boceprevir, ceritinib, clarithromycin, cobicistat, idelalisib, indinavir, itraconazole, josamycin, ketoconazole, lonafarnib, lopinavir, mibefradil, mifepristone, nefazodone, nelfinavir, nirmatrelvir/ritonavir, paritaprevir, posaconazole, ribociclib, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, tucatinib, or voriconazole.(2,3) |
APTIVUS, CLARITHROMYCIN, CLARITHROMYCIN ER, EVOTAZ, GENVOYA, ITRACONAZOLE, ITRACONAZOLE MICRONIZED, KALETRA, KETOCONAZOLE, KISQALI, KORLYM, KRAZATI, LANSOPRAZOL-AMOXICIL-CLARITHRO, LOPINAVIR-RITONAVIR, MIFEPREX, MIFEPRISTONE, NEFAZODONE HCL, NOXAFIL, OMECLAMOX-PAK, PAXLOVID, POSACONAZOLE, PREZCOBIX, RECORLEV, SPORANOX, STRIBILD, SYMTUZA, TOLSURA, TUKYSA, TYBOST, VFEND, VFEND IV, VIRACEPT, VOQUEZNA TRIPLE PAK, VORICONAZOLE, ZYDELIG, ZYKADIA |
| Atogepant/CYP3A4 Inducers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Strong, moderate, and weak CYP3A4 inducers may increase the metabolism of atogepant by CYP3A4.(1) CLINICAL EFFECTS: The concurrent use of strong, moderate, or weak CYP3A4 inducers with atogepant may result in decreased levels and clinical effectiveness of atogepant.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: The manufacturer of atogepant recommends that patients on concomitant strong, moderate, or weak CYP3A4 inducers receive atogepant 30 mg or 60 mg once daily for prevention of episodic migraines and avoid use of atogepant for prevention of chronic migraines.(1) Patients receiving concurrent therapy with CYP3A4 inducers and atogepant should be observed for decreased clinical effectiveness. DISCUSSION: In a study of healthy subjects, rifampin, a strong CYP3A4 inducer, decreased the area-under-curve (AUC) and maximum concentration (Cmax) of atogepant by 60% and 30%, respectively. Topiramate, a weak CYP3A4 inducer, decreased atogepant AUC and Cmax by 25% and 24%, respectively.(1) Strong CYP3A4 inducers linked to this monograph include: apalutamide, barbiturates, carbamazepine, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, rifampin, rifapentine, and St. John's wort. Moderate CYP3A4 inducers linked to this monograph include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, lesinurad, lorlatinib, mavacamten, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, repotrectinib, rifabutin, sotorasib, telotristat, thioridazine and tovorafenib. Weak CYP3A4 inducers linked to this monograph include: armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, darolutamide, dexamethasone, dicloxacillin, echinacea, eslicarbazepine, floxacillin, garlic, genistein, ginseng, glycyrrhizin, methylprednisolone, mobocertinib, nevirapine, omaveloxolone, oritavancin, oxcarbazepine, pioglitazone, pitolisant, quercetin, relugolix, rufinamide, sarilumab, sulfinpyrazone, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vemurafenib, vinblastine, and zanubrutinib.(1,2) |
ACTOPLUS MET, ACTOS, ALOGLIPTIN-PIOGLITAZONE, ALUNBRIG, APTIOM, ARMODAFINIL, ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, AUGTYRO, BANZEL, BEXAROTENE, BOSENTAN, BRIVIACT, BRUKINSA, BUPIVACAINE-DEXAMETH-EPINEPHRN, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALBITAL, BUTALBITAL-ACETAMINOPHEN, BUTALBITAL-ACETAMINOPHEN-CAFFE, BUTALBITAL-ASPIRIN-CAFFEINE, CAMZYOS, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CEREBYX, CLOBAZAM, DEPO-MEDROL, DEXABLISS, DEXAMETHASONE, DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE MICRO, DEXAMETHASONE INTENSOL, DEXAMETHASONE ISONICOTINATE, DEXAMETHASONE MICRONIZED, DEXAMETHASONE SOD PHOS-WATER, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE-0.9% NACL, DICLOXACILLIN SODIUM, DILANTIN, DILANTIN-125, DMT SUIK, DONNATAL, DOUBLEDEX, DUETACT, DUZALLO, EFAVIRENZ, EFAVIRENZ-EMTRIC-TENOFOV DISOP, EFAVIRENZ-LAMIVU-TENOFOV DISOP, EPITOL, EPRONTIA, EQUETRO, ERLEADA, ESLICARBAZEPINE ACETATE, ETRAVIRINE, FIORICET, FIORICET WITH CODEINE, FOSPHENYTOIN SODIUM, HEMADY, INTELENCE, KEVZARA, KIMYRSA, LIDOCIDEX-I, LORBRENA, LUMAKRAS, LYSODREN, MAS CARE-PAK, MEDROL, MEDROLOAN II SUIK, MEDROLOAN SUIK, METHYLPREDNISOLONE, METHYLPREDNISOLONE AC MICRO, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, MITOTANE, MODAFINIL, MYFEMBREE, MYSOLINE, NAFCILLIN, NAFCILLIN SODIUM, NEVIRAPINE, NEVIRAPINE ER, NUBEQA, NUVIGIL, OJEMDA, ONFI, ORBACTIV, ORGOVYX, ORIAHNN, ORILISSA, ORKAMBI, OSENI, OXCARBAZEPINE, OXCARBAZEPINE ER, OXTELLAR XR, PENTOBARBITAL SODIUM, PHENOBARBITAL, PHENOBARBITAL SODIUM, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PHENTERMINE-TOPIRAMATE ER, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED, PIOGLITAZONE HCL, PIOGLITAZONE-GLIMEPIRIDE, PIOGLITAZONE-METFORMIN, PRIFTIN, PRIMIDONE, PROVIGIL, PYRUKYND, QSYMIA, RIFABUTIN, RUFINAMIDE, SEZABY, SKYCLARYS, SOLU-MEDROL, SYMFI, SYMPAZAN, TAFINLAR, TALICIA, TAPERDEX, TARGRETIN, TAZVERIK, TEGRETOL, TEGRETOL XR, TENCON, TERBINAFINE HCL, THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE, TIBSOVO, TOPAMAX, TOPIRAMATE, TOPIRAMATE ER, TOPIRAMATE ER SPRINKLE, TPOXX (NATIONAL STOCKPILE), TRACLEER, TRILEPTAL, TROKENDI XR, TURALIO, VINBLASTINE SULFATE, VONJO, WAKIX, WELIREG, XCOPRI, XERMELO, XTANDI, ZCORT, ZELBORAF |
| Atogepant/Encorafenib; Rifampin SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Atogepant is a substrate of CYP3A4 and OATP1B1/1B3.(1) Encorafenib and rifampin are inhibitors of the OATP transporters may decrease the hepatic uptake of atogepant. Encorafenib and rifampin are also strong CYP3A4 inducers and may increase the metabolism of atogepant.(2,3) CLINICAL EFFECTS: The exact course of this interaction is unknown. When encorafenib or rifampin is first started and before CYP enzyme induction occurs, atogepant levels may increase and result in side effects from atogepant, including nausea, constipation and fatigue. After CYP3A4 enzymes are induced, atogepant levels and effectiveness may decrease.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: When used concurrently with an OATP inhibitor, the recommended atogepant dose for episodic migraine is 10 mg or 30 mg once daily, and the recommended atogepant dose for chronic migraine is 30 mg once daily. When used concurrently with a strong CYP3A4 inducer, the recommended atogepant dose for episodic migraine is 30 mg or 60 mg daily. When atogepant is used for chronic migraine, concurrent CYP3A4 inducers should be avoided.(1) Atogepant dose may need to be adjusted in the first weeks of concurrent therapy with encorafenib or rifampin. Monitor the patient for side effects and efficacy. DISCUSSION: In a clinical trial of healthy subjects, single-dose rifampin increased the atogepant area-under-curve (AUC) and maximum concentration (Cmax) by 2.85-fold and 2.23-fold, respectively.(1) In a study of healthy subjects, steady state rifampin decreased the AUC and Cmax of atogepant by 60% and 30%, respectively.(1) |
BRAFTOVI, RIFADIN, RIFAMPIN |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Atogepant/OATP1B1-3 Inhibitors SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Atogepant is a substrate of OATP1B1 and 1B3. Inhibitors of these transporters may increase the GI absorption and/or decrease the hepatic uptake of atogepant.(1) CLINICAL EFFECTS: Concurrent use of OATP1B1 or 1B3 inhibitors may result in elevated levels of and side effects from atogepant, including nausea, constipation and fatigue.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of atogepant states that, when used concurrently with an OATP inhibitor for prevention of episodic migraine, the atogepant dose should be limited to 10 mg or 30 mg once daily. When used concurrently with an OATP inhibitor for prevention of chronic migraines, the atogepant dose should be limited to 30 mg once daily.(1) DISCUSSION: In a clinical trial of healthy subjects, single-dose rifampin, an OATP inhibitor, increased the atogepant area-under-curve (AUC) and maximum concentration (Cmax) by 2.85-fold and 2.23-fold, respectively.(1) OATP1B1 and 1B3 inhibitors include asciminib, atazanavir, belumosudil, cyclosporine, darunavir, eltrombopag, erythromycin, gemfibrozil, glecaprevir-pibrentasvir, ledipasvir, leflunomide, leniolisib, letermovir, paritaprevir, resmetirom, ritonavir, roxadustat, simeprevir, sofosbuvir, teriflunomide, vadadustat, velpatasvir, and voclosporin.(1,2) |
ALVAIZ, ARAVA, ATAZANAVIR SULFATE, AUBAGIO, CYCLOSPORINE, CYCLOSPORINE MODIFIED, DARUNAVIR, E.E.S. 200, E.E.S. 400, ELTROMBOPAG OLAMINE, EPCLUSA, ERY-TAB, ERYPED 200, ERYPED 400, ERYTHROCIN LACTOBIONATE, ERYTHROCIN STEARATE, ERYTHROMYCIN, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN LACTOBIONATE, EVOTAZ, GEMFIBROZIL, GENGRAF, HARVONI, JOENJA, KALETRA, LEDIPASVIR-SOFOSBUVIR, LEFLUNICLO, LEFLUNOMIDE, LOPID, LOPINAVIR-RITONAVIR, LUPKYNIS, MAVYRET, NEORAL, NORVIR, PREVYMIS, PREZCOBIX, PREZISTA, PROMACTA, REYATAZ, REZDIFFRA, REZUROCK, RITONAVIR, SANDIMMUNE, SCEMBLIX, SOFOSBUVIR-VELPATASVIR, SOVALDI, SYMTUZA, TERIFLUNOMIDE, VAFSEO, VOSEVI |
The following contraindication information is available for QULIPTA (atogepant):
Drug contraindication overview.
*Contraindicated in patients with a history of hypersensitivity to atogepant or any of the inactive ingredients in the formulation.
*Contraindicated in patients with a history of hypersensitivity to atogepant or any of the inactive ingredients in the formulation.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Child-pugh class C hepatic impairment |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Disease of liver |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypertension |
| Raynaud's phenomenon |
The following adverse reaction information is available for QULIPTA (atogepant):
Adverse reaction overview.
Common adverse reactions reported in >=4% of patients receiving atogepant in clinical studies include nausea, constipation, and fatigue/somnolence.
Common adverse reactions reported in >=4% of patients receiving atogepant in clinical studies include nausea, constipation, and fatigue/somnolence.
There are 3 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Anaphylaxis Dyspnea |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests |
There are 12 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Constipation Fatigue Nausea |
Anorexia Facial edema Pruritus of skin Skin rash Urticaria |
| Rare/Very Rare |
|---|
|
Dizziness Hypersensitivity drug reaction Hypertension Raynaud's phenomenon |
The following precautions are available for QULIPTA (atogepant):
Safety and efficacy of atogepant have not been established in pediatric patients.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no adequate data on the developmental risk associated with the use of atogepant in pregnant women. Based on animal studies, the drug may cause fetal harm. In animal studies, adverse effects on embryofetal development (e.g., decreased fetal and offspring body weight in rats, increased fetal structural variations in rabbits) were observed following administration of the drug during pregnancy and lactation at dosages higher than those used clinically. Published data suggest that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.
It is not known whether atogepant is distributed into human milk; the drug is distributed into milk in rats. The effects of atogepant on the breast-fed infant and on milk production are not known. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for atogepant and any potential adverse effects on the breast-fed infant from the drug or from the underlying maternal condition.
Clinical studies of atogepant did not include sufficient numbers of patients >=65 years of age to determine whether they respond differently than younger adults. In pharmacokinetic studies, no clinically important differences in the pharmacokinetics of atogepant were observed between geriatric individuals and younger adults. The manufacturer states that, in general, dosage selection for geriatric patients should be cautious and start at the low end of the dosage range.
The following prioritized warning is available for QULIPTA (atogepant):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for QULIPTA (atogepant)'s list of indications:
| Migraine prevention | |
| G43 | Migraine |
| G43.0 | Migraine without aura |
| G43.00 | Migraine without aura, not intractable |
| G43.001 | Migraine without aura, not intractable, with status migrainosus |
| G43.009 | Migraine without aura, not intractable, without status migrainosus |
| G43.01 | Migraine without aura, intractable |
| G43.011 | Migraine without aura, intractable, with status migrainosus |
| G43.019 | Migraine without aura, intractable, without status migrainosus |
| G43.1 | Migraine with aura |
| G43.10 | Migraine with aura, not intractable |
| G43.101 | Migraine with aura, not intractable, with status migrainosus |
| G43.109 | Migraine with aura, not intractable, without status migrainosus |
| G43.11 | Migraine with aura, intractable |
| G43.111 | Migraine with aura, intractable, with status migrainosus |
| G43.119 | Migraine with aura, intractable, without status migrainosus |
| G43.4 | Hemiplegic migraine |
| G43.40 | Hemiplegic migraine, not intractable |
| G43.401 | Hemiplegic migraine, not intractable, with status migrainosus |
| G43.409 | Hemiplegic migraine, not intractable, without status migrainosus |
| G43.41 | Hemiplegic migraine, intractable |
| G43.411 | Hemiplegic migraine, intractable, with status migrainosus |
| G43.419 | Hemiplegic migraine, intractable, without status migrainosus |
| G43.5 | Persistent migraine aura without cerebral infarction |
| G43.50 | Persistent migraine aura without cerebral infarction, not intractable |
| G43.501 | Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus |
| G43.509 | Persistent migraine aura without cerebral infarction, not intractable, without status migrainosus |
| G43.51 | Persistent migraine aura without cerebral infarction, intractable |
| G43.511 | Persistent migraine aura without cerebral infarction, intractable, with status migrainosus |
| G43.519 | Persistent migraine aura without cerebral infarction, intractable, without status migrainosus |
| G43.6 | Persistent migraine aura with cerebral infarction |
| G43.60 | Persistent migraine aura with cerebral infarction, not intractable |
| G43.601 | Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus |
| G43.609 | Persistent migraine aura with cerebral infarction, not intractable, without status migrainosus |
| G43.61 | Persistent migraine aura with cerebral infarction, intractable |
| G43.611 | Persistent migraine aura with cerebral infarction, intractable, with status migrainosus |
| G43.619 | Persistent migraine aura with cerebral infarction, intractable, without status migrainosus |
| G43.7 | Chronic migraine without aura |
| G43.70 | Chronic migraine without aura, not intractable |
| G43.701 | Chronic migraine without aura, not intractable, with status migrainosus |
| G43.709 | Chronic migraine without aura, not intractable, without status migrainosus |
| G43.71 | Chronic migraine without aura, intractable |
| G43.711 | Chronic migraine without aura, intractable, with status migrainosus |
| G43.719 | Chronic migraine without aura, intractable, without status migrainosus |
| G43.8 | Other migraine |
| G43.80 | Other migraine, not intractable |
| G43.801 | Other migraine, not intractable, with status migrainosus |
| G43.809 | Other migraine, not intractable, without status migrainosus |
| G43.81 | Other migraine, intractable |
| G43.811 | Other migraine, intractable, with status migrainosus |
| G43.819 | Other migraine, intractable, without status migrainosus |
| G43.82 | Menstrual migraine, not intractable |
| G43.821 | Menstrual migraine, not intractable, with status migrainosus |
| G43.829 | Menstrual migraine, not intractable, without status migrainosus |
| G43.83 | Menstrual migraine, intractable |
| G43.831 | Menstrual migraine, intractable, with status migrainosus |
| G43.839 | Menstrual migraine, intractable, without status migrainosus |
| G43.9 | Migraine, unspecified |
| G43.90 | Migraine, unspecified, not intractable |
| G43.901 | Migraine, unspecified, not intractable, with status migrainosus |
| G43.909 | Migraine, unspecified, not intractable, without status migrainosus |
| G43.91 | Migraine, unspecified, intractable |
| G43.911 | Migraine, unspecified, intractable, with status migrainosus |
| G43.919 | Migraine, unspecified, intractable, without status migrainosus |
| G43.B | Ophthalmoplegic migraine |
| G43.B0 | Ophthalmoplegic migraine, not intractable |
| G43.B1 | Ophthalmoplegic migraine, intractable |
| G43.C | Periodic headache syndromes in child or adult |
| G43.C0 | Periodic headache syndromes in child or adult, not intractable |
| G43.C1 | Periodic headache syndromes in child or adult, intractable |
| G43.D | Abdominal migraine |
| G43.D0 | Abdominal migraine, not intractable |
| G43.D1 | Abdominal migraine, intractable |
| G43.E | Chronic migraine with aura |
| G43.E0 | Chronic migraine with aura, not intractable |
| G43.E01 | Chronic migraine with aura, not intractable, with status migrainosus |
| G43.E09 | Chronic migraine with aura, not intractable, without status migrainosus |
| G43.E1 | Chronic migraine with aura, intractable |
| G43.E11 | Chronic migraine with aura, intractable, with status migrainosus |
| G43.E19 | Chronic migraine with aura, intractable, without status migrainosus |
Formulary Reference Tool